Showing results (471-480 of 831) with videos related to
Sort By:
Pageof 84
Blood|July 14, 2011
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemiaSameer A Parikh, Michael J Keating, Susan O'Brien, et al.Cancer|May 16, 2006
Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy aloneApostolia M Tsimberidou, Daniel Catovsky, Ellen Schlette, et al.Blood|September 6, 2007
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitorsJorge Cortes, Elias Jabbour, Hagop Kantarjian, et al.Cancer|July 29, 2015
Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsMusa Yilmaz, Amit Lahoti, Susan O'Brien, et al.Haematologica|February 16, 2015
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaNaval Daver, Deborah Thomas, Farhad Ravandi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemiaTait D Shanafelt, Tim G Call, Clive S Zent, et al.Journal of the American Academy of Dermatology|July 19, 2020
Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemiaGeffen Kleinstern, Abdul Rishi, Sara J Achenbach, et al.Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapyStefan Faderl, Deborah Ann Thomas, Susan O'Brien, et al.Cancer|May 13, 2008
Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicityAmar Safdar, Gilhen H Rodriguez, Adriana M Rueda, et al.Blood|March 14, 2009
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phaseCarmen Fava, Hagop M Kantarjian, Elias Jabbour, et al.Pageof 84